Heart Failure Clinical Trials

Find Heart Failure Clinical Trials Near You

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Clinical diagnosis of HF

• No plan for titration/change of heart failure medical or device therapies during the study period.

• Absence of non-elective hospitalizations in the previous 2 weeks

• At optimal volume status by symptoms, exam, and dry weight.

• Serum potassium ≤ 5.0 mmol/L

• Serum sodium ≥ 130 mEq/L

• Age \> 18 years

• Hemoglobin ≥8 g/dL

• Objective evidence of diuretic resistance to a 10mg bumetanide challenge, defined as:

‣ FENa \<10% and total sodium output \<150mmol and

⁃ At least one of the following criteria:

∙ 1\. Chronic home furosemide dose \> or equal to 80mg furosemide equivalents daily 2. eGFR \< 60ml/min 3. Serum chloride \<100mmol/L 4. FENa \<5% and total sodium output \<75mmol on the 2 hour screening

Locations
United States
Connecticut
Yale University
RECRUITING
New Haven
Contact Information
Primary
Veena Rao
veena.s.rao@yale.edu
203-737-3571
Time Frame
Start Date: 2023-08-10
Estimated Completion Date: 2028-06-01
Participants
Target number of participants: 50
Treatments
Placebo_comparator: Placebo/ Placebo
This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Active_comparator: Placebo/ Amiloride
This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Active_comparator: Placebo/ Bendroflumethiazide
This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Active_comparator: Bendroflumethiazide/ Amiloride
This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: Yale University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials